Phone:020-31155029| Tech Support:tech@tomums.cn| E-mail:sales@tomums.cn
首页 > 产品 > 活性小分子 > Proteases > Delanzomib (CEP-18770)

Delanzomib (CEP-18770)

商品编号: TS0515
图示 货号 库存 价格(¥) 数量

备注:

如需更大包装,请联系销售人员,大包装有极大的折扣优惠!

质量文档

详细介绍

l  基本信息

产品名称

Delanzomib

一般描述

Delanzomib is an orally active inhibitor of the chymotrypsin-like activity of proteasome with IC50 of 3.8 nM, with only marginal inhibition of the tryptic and peptidylglutamyl activities of the proteosome.

别 称

CEP-18770

纯 度

≥98.0%(HPLC)

CAS NO.

847499-27-8

分子式

C21H28BN3O5

分子量

413.281

适用范围

生物试剂,适用于细胞培养等

l  理化信息

外 观

白色或类白色至浅棕色固体

溶解性(25°C)

DMSO

≥50mg/ml

乙醇

≥50mg/ml

Very slightly soluble

l  生物学信息

生物活性/药理作用

Delanzomib is an orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Delanzomib represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the tranion factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and tranional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. In vitro studies indicate that this agent exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells relative to the proteasome inhibitor bortezomib. The intracellular protein IkappaBalpha functions as a primary inhibitor of the proinflammatory tranion factor NF-kappaB.

l  存储

存储温度

-20°C

l  注意事项及免责声明

本产品仅用于实验研究,不得作为药物使用,不得用于家用或其它用途。

l  参考文献

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.    https://www.ncbi.nlm.nih.gov